Issue 9, 2021
From the journal:

RSC Advances

Retraction: Aclarubicin regulates glioma cell growth and DNA damage through the SIRT1/PI3K/AKT signaling pathway

Laura Fishera  

a Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, UK
E-mail: advances-rsc@rsc.org

Abstract

Retraction of ‘Aclarubicin regulates glioma cell growth and DNA damage through the SIRT1/PI3K/AKT signaling pathway’ by Jun-Feng Huo et al., RSC Adv., 2019, 9, 28775–28782, DOI: 10.1039/C9RA05572J.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D1RA90038B
Article type
Retraction
Submitted
18 Jan 2021
Accepted
18 Jan 2021
First published
26 Jan 2021
This article is Open Access
Creative Commons BY license

RSC Adv., 2021,11, 5022-5022

Permissions

Request permissions

Retraction: Aclarubicin regulates glioma cell growth and DNA damage through the SIRT1/PI3K/AKT signaling pathway

L. Fisher, RSC Adv., 2021, 11, 5022 DOI: 10.1039/D1RA90038B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements